Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (433)	12/19/2000 11:19:16 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Asthma and CHF, from OSIP 10-K, filed today...... <TABLE> <CAPTION> DISEASE AREA/PRODUCT GENE TARGET STATUS(1) COLLABORATOR ------------ ----------- --------- ------------ <S> <C> <C> <C> CANCER OSI-774 Epidermal growth factor receptor Phase II OSI-Owned CP-609,754 Farnesyl transferase Phase I Pfizer CP-663,427 Farnesyl transferase IND Track Pfizer CP-547,032 Vascular endothelial growth factor receptor IND Track Pfizer CP-673,451 Platelet-derived growth factor receptor IND Track Pfizer RESPIRATORY/ASTHMA OSIC-113760 Adenosine A(1) receptor IND Track OSI-Owned M810309 Interleukin-4 gene expression IND Track Aventis CHOLESTEROL LOWERING HMR 1171/ AVE Low density lipoprotein receptor gene IND Track Aventis 9103 expression COSMECEUTICALS AD-01-728 Skin pigmentation IND Track Anaderm CONGESTIVE HEART FAILURE OSIC-0961370 Adenosine A(1) receptor IND Track Solvay </TABLE>